Epidemiology and Outcomes in Critically Ill Patients with Human Immunodeficiency Virus Infection in the Era of Combination Antiretroviral Therapy

Purpose. The impact of critical illness on survival of HIV-infected patients in the era of antiretroviral therapy remains uncertain. We describe the epidemiology of critical illness in this population and identify predictors of mortality. Materials and Methods. Retrospective cohort of HIV-infected p...

Full description

Saved in:
Bibliographic Details
Main Authors: Shannon L. Turvey, Sean M. Bagshaw, Dean T. Eurich, Wendy I. Sligl
Format: Article
Language:English
Published: Wiley 2017-01-01
Series:Canadian Journal of Infectious Diseases and Medical Microbiology
Online Access:http://dx.doi.org/10.1155/2017/7868954
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849683363213869056
author Shannon L. Turvey
Sean M. Bagshaw
Dean T. Eurich
Wendy I. Sligl
author_facet Shannon L. Turvey
Sean M. Bagshaw
Dean T. Eurich
Wendy I. Sligl
author_sort Shannon L. Turvey
collection DOAJ
description Purpose. The impact of critical illness on survival of HIV-infected patients in the era of antiretroviral therapy remains uncertain. We describe the epidemiology of critical illness in this population and identify predictors of mortality. Materials and Methods. Retrospective cohort of HIV-infected patients was admitted to intensive care from 2002 to 2014. Patient sociodemographics, comorbidities, case-mix, illness severity, and 30-day mortality were captured. Multivariable Cox regression analyses were performed to identify predictors of mortality. Results. Of 282 patients, mean age was 44 years (SD 10) and 169 (59%) were male. Median (IQR) CD4 count and plasma viral load (PVL) were 125 cells/mm3 (30–300) and 28,000 copies/mL (110–270,000). Fifty-five (20%) patients died within 30 days. Factors independently associated with mortality included APACHE II score (adjusted hazard ratio [aHR] 1.12; 95% CI 1.08–1.16; p<0.001), cirrhosis (aHR 2.30; 95% CI 1.12–4.73; p=0.024), coronary artery disease (aHR 6.98; 95% CI 2.20–22.13; p=0.001), and duration of HIV infection (aHR 1.07 per year; 95% CI 1.02–1.13; p=0.01). CD4 count and PVL were not associated with mortality. Conclusions. Mortality from an episode of critical illness in HIV-infected patients remains high but appears to be driven by acute illness severity and HIV-unrelated comorbid disease rather than degree of immune suppression.
format Article
id doaj-art-dbfe79b89d9c4ec78817ce24eb4ecc02
institution DOAJ
issn 1712-9532
1918-1493
language English
publishDate 2017-01-01
publisher Wiley
record_format Article
series Canadian Journal of Infectious Diseases and Medical Microbiology
spelling doaj-art-dbfe79b89d9c4ec78817ce24eb4ecc022025-08-20T03:23:56ZengWileyCanadian Journal of Infectious Diseases and Medical Microbiology1712-95321918-14932017-01-01201710.1155/2017/78689547868954Epidemiology and Outcomes in Critically Ill Patients with Human Immunodeficiency Virus Infection in the Era of Combination Antiretroviral TherapyShannon L. Turvey0Sean M. Bagshaw1Dean T. Eurich2Wendy I. Sligl3Division of Infectious Diseases, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, CanadaDepartment of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, CanadaSchool of Public Health, University of Alberta, Edmonton, AB, CanadaDivision of Infectious Diseases, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, CanadaPurpose. The impact of critical illness on survival of HIV-infected patients in the era of antiretroviral therapy remains uncertain. We describe the epidemiology of critical illness in this population and identify predictors of mortality. Materials and Methods. Retrospective cohort of HIV-infected patients was admitted to intensive care from 2002 to 2014. Patient sociodemographics, comorbidities, case-mix, illness severity, and 30-day mortality were captured. Multivariable Cox regression analyses were performed to identify predictors of mortality. Results. Of 282 patients, mean age was 44 years (SD 10) and 169 (59%) were male. Median (IQR) CD4 count and plasma viral load (PVL) were 125 cells/mm3 (30–300) and 28,000 copies/mL (110–270,000). Fifty-five (20%) patients died within 30 days. Factors independently associated with mortality included APACHE II score (adjusted hazard ratio [aHR] 1.12; 95% CI 1.08–1.16; p<0.001), cirrhosis (aHR 2.30; 95% CI 1.12–4.73; p=0.024), coronary artery disease (aHR 6.98; 95% CI 2.20–22.13; p=0.001), and duration of HIV infection (aHR 1.07 per year; 95% CI 1.02–1.13; p=0.01). CD4 count and PVL were not associated with mortality. Conclusions. Mortality from an episode of critical illness in HIV-infected patients remains high but appears to be driven by acute illness severity and HIV-unrelated comorbid disease rather than degree of immune suppression.http://dx.doi.org/10.1155/2017/7868954
spellingShingle Shannon L. Turvey
Sean M. Bagshaw
Dean T. Eurich
Wendy I. Sligl
Epidemiology and Outcomes in Critically Ill Patients with Human Immunodeficiency Virus Infection in the Era of Combination Antiretroviral Therapy
Canadian Journal of Infectious Diseases and Medical Microbiology
title Epidemiology and Outcomes in Critically Ill Patients with Human Immunodeficiency Virus Infection in the Era of Combination Antiretroviral Therapy
title_full Epidemiology and Outcomes in Critically Ill Patients with Human Immunodeficiency Virus Infection in the Era of Combination Antiretroviral Therapy
title_fullStr Epidemiology and Outcomes in Critically Ill Patients with Human Immunodeficiency Virus Infection in the Era of Combination Antiretroviral Therapy
title_full_unstemmed Epidemiology and Outcomes in Critically Ill Patients with Human Immunodeficiency Virus Infection in the Era of Combination Antiretroviral Therapy
title_short Epidemiology and Outcomes in Critically Ill Patients with Human Immunodeficiency Virus Infection in the Era of Combination Antiretroviral Therapy
title_sort epidemiology and outcomes in critically ill patients with human immunodeficiency virus infection in the era of combination antiretroviral therapy
url http://dx.doi.org/10.1155/2017/7868954
work_keys_str_mv AT shannonlturvey epidemiologyandoutcomesincriticallyillpatientswithhumanimmunodeficiencyvirusinfectionintheeraofcombinationantiretroviraltherapy
AT seanmbagshaw epidemiologyandoutcomesincriticallyillpatientswithhumanimmunodeficiencyvirusinfectionintheeraofcombinationantiretroviraltherapy
AT deanteurich epidemiologyandoutcomesincriticallyillpatientswithhumanimmunodeficiencyvirusinfectionintheeraofcombinationantiretroviraltherapy
AT wendyisligl epidemiologyandoutcomesincriticallyillpatientswithhumanimmunodeficiencyvirusinfectionintheeraofcombinationantiretroviraltherapy